In announcing unsuccessful top-line results in its Phase 3 trial...

In announcing unsuccessful top-line results in its Phase 3 trial of pimavanserin in negative symptoms of schizophrenia, Acadia CEO Steve Davis said that the Company doesn’t intend to conduct any further clinical trials with pimavanserin.

Pimavanserin is still currently being studied in half a dozen or so trials but these are almost all in studies sponsored by others (eg. Veteran Affairs Office of R & D, University of Texas, State University of New York).

An exception to this is Acadia’s 6 week long, double-blind, placebo-controlled Phase 2/3 study and 12 month long open label extension study in 228 patients investigating the use of pimavanserin in the treatment of Irritability Associated with Autism Spectrum Disorder. The main study is estimated to complete in June this year with the extension study estimated to run until July next year. The international trial is recruiting in the US, Australia, France, Italy, Spain Hungary and Poland.

I don’t understand. Acadia has never mentioned these studies in announcements, Earnings Calls or Annual Reports and never included them in its pipeline. I’ve never heard analysts raise questions about these studies. Nor has Irritability Associated with Autism Spectrum Disorder been mentioned by anyone this week as a remaining “live” clinical program for pimavanserin. What happens if results are good?

Perhaps someone else is able to shed light on this?

Further to the issue of the failed pimavanserin results this week, I note that Barrons says that roughly two-thirds of all analysts tracking ACAD are still bullish, rating it at Buy or equivalent with some resting their thesis on Daybue.

https://clinicaltrials.gov/search?c...utism Spectrum Disorder&intr=Pimavanserin

https://www.barrons.com/articles/acadia-stock-price-drug-trial-ef61703a

https://au.investing.com/news/stock...adia-shares-target-to-19-from-25-93CH-3152346